NasdaqGS - Delayed Quote • USD
AstraZeneca PLC (AZN)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:36 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
45,811,000.00
45,811,000.00
44,351,000.00
37,417,000.00
26,617,000.00
Cost of Revenue
8,268,000.00
8,268,000.00
12,391,000.00
12,437,000.00
5,299,000.00
Gross Profit
37,543,000.00
37,543,000.00
31,960,000.00
24,980,000.00
21,318,000.00
Operating Expense
28,821,000.00
28,821,000.00
27,448,000.00
25,119,000.00
17,402,000.00
Operating Income
8,722,000.00
8,722,000.00
4,512,000.00
-139,000.00
3,916,000.00
Net Non Operating Interest Income Expense
-1,288,000.00
-1,288,000.00
-1,249,000.00
-1,233,000.00
-1,189,000.00
Pretax Income
6,899,000.00
6,899,000.00
2,501,000.00
-265,000.00
3,916,000.00
Tax Provision
938,000.00
938,000.00
-792,000.00
-380,000.00
772,000.00
Net Income Common Stockholders
5,955,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Diluted NI Available to Com Stockholders
5,955,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Basic EPS
1.92
--
1.06
0.04
1.22
Diluted EPS
1.91
--
1.05
0.04
1.22
Basic Average Shares
3,098,000.00
--
3,096,000.00
2,836,000.00
2,624,000.00
Diluted Average Shares
3,124,000.00
--
3,120,000.00
2,854,000.00
2,626,000.00
Total Operating Income as Reported
8,193,000.00
8,193,000.00
3,757,000.00
1,056,000.00
5,162,000.00
Rent Expense Supplemental
301,000.00
301,000.00
268,000.00
262,000.00
228,000.00
Total Expenses
37,089,000.00
37,089,000.00
39,839,000.00
37,556,000.00
22,701,000.00
Net Income from Continuing & Discontinued Operation
5,955,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Normalized Income
6,375,540.00
6,375,540.00
3,888,210.00
-852,710.00
2,192,424.92
Interest Income
301,000.00
301,000.00
81,000.00
43,000.00
83,000.00
Interest Expense
1,589,000.00
1,589,000.00
1,330,000.00
1,276,000.00
1,272,000.00
Net Interest Income
-1,288,000.00
-1,288,000.00
-1,249,000.00
-1,233,000.00
-1,189,000.00
EBIT
8,488,000.00
8,488,000.00
3,831,000.00
1,011,000.00
5,188,000.00
EBITDA
13,422,000.00
13,422,000.00
9,085,000.00
5,113,000.00
8,084,000.00
Reconciled Cost of Revenue
8,268,000.00
8,268,000.00
12,391,000.00
12,437,000.00
5,299,000.00
Reconciled Depreciation
4,934,000.00
4,934,000.00
5,254,000.00
4,102,000.00
2,896,000.00
Net Income from Continuing Operation Net Minority Interest
5,955,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Total Unusual Items Excluding Goodwill
-489,000.00
-489,000.00
-741,000.00
1,191,000.00
1,250,000.00
Total Unusual Items
-489,000.00
-489,000.00
-741,000.00
1,191,000.00
1,250,000.00
Normalized EBITDA
13,911,000.00
13,911,000.00
9,826,000.00
3,922,000.00
6,834,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-68,460.00
-68,460.00
-140,790.00
226,290.00
246,424.92
12/31/2020 - 5/12/1993
Yahoo Finance Plus Essential access required. Unlock Access
Related Tickers
NVS Novartis AG
94.36
+1.93%
GSK GSK plc
39.75
+1.22%
SNY Sanofi
46.30
+2.00%
MRK Merck & Co., Inc.
125.78
+0.44%
BMY Bristol-Myers Squibb Company
48.93
+1.30%
GILD Gilead Sciences, Inc.
66.76
+0.91%
AMGN Amgen Inc.
268.93
+2.35%
ABBV AbbVie Inc.
166.41
+1.06%
BIIB Biogen Inc.
194.38
+2.03%
LLY Eli Lilly and Company
726.31
-2.63%